Features of the PC and SC model of care for methadone treatment (ANRS Methaville trial).

<p>Features of the PC and SC model of care for methadone treatment (ANRS Methaville trial).</p

Patient characteristics by induction arm (SC and PC) at baseline (ANRS Methaville trial).

<p>*during the previous 4 weeks.</p><p>**AUDIT score ≥7 for males and ≥6 for females.</p><p>***CES-D score>17 for males and>23 for females.</p><p>****among those who had already done a test.</p><p>Patient characteristics by induction arm (SC and PC) at baseline (ANRS Methaville trial).</p

Odds ratio from the adjusted mixed model for abstinence from opioids use during the treatment (n = 615 visits and 188 patients).

<p>Odds ratio from the adjusted mixed model for abstinence from opioids use during the treatment (n = 615 visits and 188 patients).</p

Factors associated with inconsistent condom use among HIV-infected patients reporting sex with a main or casual partner(s) - either HIV negative or of unknown status during the first year of antiretroviral therapy in Cameroon: univariate and multivariate analyses using mixed-effect logistic models (212 patients, 344 visits).

<p>OR  =  crude odds ratio, AOR  =  adjusted odds ratio, IQR: interquartile range,</p>*<p>included in multivariate analysis,</p>a<p>during the previous 12 months,</p>b<p>consumption of three big bottles and/or six glasses of alcoholic beverages or more on any one occasion,</p>c<p>level 1 or 2 on a ten-point scale <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0036118#pone.0036118-SinghManoux1" target="_blank">[15]</a>,</p>d<p>score range 0–60, higher values denote more depressive symptoms <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0036118#pone.0036118-Radloff1" target="_blank">[17]</a>.</p

Flow chart of ANRS Methaville trial.

<p>Flow chart of ANRS Methaville trial.</p

Retention in methadone maintenance treatment in patients (who completed the induction phase) in primary care (PC) versus those who started in specialized care (SC).

<p>Retention in methadone maintenance treatment in patients (who completed the induction phase) in primary care (PC) versus those who started in specialized care (SC).</p

Cross tabulation between incomplete virological suppression (defined as having had at least one detectable viral load (≥40 copies/ml) during the previous 6 months) and inconsistent condom use at each follow up time point (Stratall ANRS 12110/ESTHER trial, 250 patients, 473 visits).

<p>ICU = Inconsistent condom use; VL = Viral Load.</p>*<p>As viral load suppression was not defined at M0, figures reported at M0 are related to No. (%) of patients having an undetectable Viral Load (HIV RNA <40copies/ml).</p>**<p>As viral load suppression was not defined at M0, figures reported at M0 are related to No. (%) of patients having a detectable Viral Load (HIV RNA≥40copies/ml).</p

Factors associated with the susceptibility to transmitting HIV during the first 24 months of antiretroviral therapy in Cameroon: univariate and multivariate analyses using mixed-effects logistic models (Stratall ANRS 12110/ESTHER trial, 250 patients, 473 visits).

<p>OR = odds ratio; AOR = adjusted odds ratio; IQR = interquartile range; CLIN = clinical monitoring alone; LAB = clinical and laboratory monitoring.</p><p>^aOR per 10-year increase;</p>b<p>Level 1 or 2 on a ten-point scale;</p>c<p>Level 1 to 5 on a 6-point visual scale;</p>d<p>CES-D score>16.</p><p>+OR per one-symptom addition,</p><p>++OR for an extra 6 months on ART.</p

Time trend of the proportion of patients with incomplete virological suppression (defined as having had a least one detectable viral load (≥40 copies/ml) during the previous 6 months) over the first 24 months (Stratall ANRS 12110/ESTHER trial, 250 patients, 473 visits).

<p>Time trend of the proportion of patients with incomplete virological suppression (defined as having had a least one detectable viral load (≥40 copies/ml) during the previous 6 months) over the first 24 months (Stratall ANRS 12110/ESTHER trial, 250 patients, 473 visits).</p

Time trend of the proportion of patients susceptible to transmitting HIV (i.e. reporting both inconsistent condom use and incomplete virological suppression) over the first 24 months of ART (Stratall ANRS 12110/ESTHER trial, 250 patients, 473 visits).

<p>Time trend of the proportion of patients susceptible to transmitting HIV (i.e. reporting both inconsistent condom use and incomplete virological suppression) over the first 24 months of ART (Stratall ANRS 12110/ESTHER trial, 250 patients, 473 visits).</p